Edition:
India

Enzo Biochem Inc (ENZ.N)

ENZ.N on New York Stock Exchange

8.80USD
13 Dec 2017
Change (% chg)

$0.08 (+0.92%)
Prev Close
$8.72
Open
$8.77
Day's High
$8.94
Day's Low
$8.77
Volume
51,183
Avg. Vol
54,539
52-wk High
$12.04
52-wk Low
$6.27

Summary

Name Age Since Current Position

Barry Weiner

67 2009 President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director

Elazar Rabbani

74 2009 Chairman of the Board, Chief Executive Officer, Secretary

James O'Brien

51 2015 Executive Vice President - Finance

Bruce Dey

59 2016 Vice President - Sales and Marketing, Enzo Clinical Labs

Dieter Schapfel

54 2014 Chief Medical Director, Enzo Clinical Labs

Gregory Bortz

47 2017 Lead Independent Director

Bruce Hanna

74 2017 Independent Director

Dov Perlysky

55 2012 Independent Director

Steve Anreder

IR Contact Officer

Biographies

Name Description

Barry Weiner

Mr. Barry W. Weiner serves as President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director of the Company. He has served as the Company’s President since 1996, and previously held the position of Executive Vice President. Before his employment with Enzo Biochem, he worked in several managerial and marketing positions at the Colgate Palmolive Company. Mr. Weiner is a member of the New York Biotechnology Association. He received his Bachelor of Arts degree in Economics from New York University and his Master of Business Administration in Finance from Boston University.

Elazar Rabbani

Dr. Elazar Rabbani, Ph.D., is the Chairman of the Board, Chief Executive Officer, Secretary of the Company. He has authored numerous scientific publications in the field of molecular biology, in particular, nucleic acid labeling and detection. He is also the lead inventor of many of the Company’s pioneering patents covering a wide range of technologies and products. Dr. Rabbani received his Bachelor of Arts degree from New York University in Chemistry and his Ph.D. in Biochemistry from Columbia University. He is a member of the American Society for Microbiology.

James O'Brien

Mr. James M. O'Brien is an Executive Vice President - Finance of the Company. From 2010 to 2013, Mr. O’Brien was Vice President and Corporate Controller for Allergen, plc. (formally Actavis, plc) a global specialty pharmaceutical company. From 1998 to 2010, Mr. O’Brien held senior level finance leadership roles at Nycomed US, Aptuit, Inc., Purdue Pharma LLP and Bristol Myers Squibb Company. From 1988 to 1998, Mr. O’Brien was with PricewaterhouseCoopers LLP. He received his Bachelor of Accounting degree from George Washington University and his Master of Business Administration from Fordham University. Mr. O’Brien is a Certified Public Accountant.

Bruce Dey

Mr. Bruce A. Dey is Vice President - Sales and Marketing, Enzo Clinical Labs of the company. Prior to joining Enzo Clinical Labs, Mr. Dey served as Vice President, Sales & Marketing for CDS Laboratories from 1989 to 2001, which was acquired by Quest Diagnostics in November 2001. He began his career with SmithKline Beecham Clinical Laboratories. Mr. Dey earned a Bachelor of Science in Economics and a Master of Business Administration from The State University of New York at Albany.

Dieter Schapfel

Dr. Dieter Schapfel, M.D., is Chief Medical Director, Enzo Clinical Labs of the company. Dr. Schapfel served as Medical Director of Pathology at Southside Hospital–North Shore/Long Island Jewish Health System from 2006 to 2012. Dr. Schapfel served as a staff pathologist at Huntington Hospital from January 2004 to June 2006. Dr. Schapfel served as Director of Pathology and Medical Affairs and the College of American Pathologists Director of Pathology, Dublin, Ireland and Farmingdale, NY for Icon Laboratories from February 2002 to October 2003. Dr. Schapfel is a graduate of the State University of New York at Stony Brook, College of Medicine, where he also served his residency. He is a diplomat of the American Board of Pathology with certification in Anatomic and Clinical Pathology and is also a diplomat of The National Board of Medical Examiners.

Gregory Bortz

Mr. Gregory M. Bortz is Lead Independent Director of the Company. Mr. Bortz is the founder of the CREO group of companies (“CREO”) and serves as CREO’s managing partner. CREO’s interests include a combination of private equity and hedge fund investments. On the private equity side, CREO is currently investing through its third fund, CREO Capital Partners Fund III, L.P. Under Mr. Bortz’s leadership, CREO has achieved successful exits from several private equity investments. CREO’s success is driven by its strategy of acquiring middle market companies at reasonable prices, strengthening and improving their operations and balance sheets and adding scale through selective, accretive mergers and acquisitions. Mr. Bortz serves as a board member of the companies in CREO’s private equity portfolio. In addition, Mr. Bortz serves as the Chief Investment Officer of the CREO Select Opportunities Fund, a hedge fund that focuses on investing in public fixed income and equity securities. From October 2000 to February 2005, Mr. Bortz was Senior Vice President, Investment Banking Division, of Lehman Brothers, Inc., an international investment bank. During his tenure at Lehman Brothers, Mr. Bortz was involved in numerous public and private debt and equity offerings, mergers and acquisitions, and restructurings. Prior to joining Lehman Brothers, Mr. Bortz held the position of Vice President of Investment Banking at Credit Suisse First Boston, an international investment bank, from January 1998 to October 2000. Mr. Bortz also previously held the position of Manager at the accounting firm of Ernst and Young (1994–1997) and Senior at the public accounting firm of Arthur Andersen (1993–1994), both in those firms’ respective audit groups. Mr. Bortz was qualified as a chartered accountant in England and Wales as well as in South Africa. He graduated with honors from the University of Cape Town with a Bachelors of Business Science in Finance and holds a Postgraduate Diploma in Accounting from that same institution.

Bruce Hanna

Dr. Bruce A. Hanna, Ph.D., is Independent Director of the Company. He is currently a Clinical Professor of Pathology and Clinical Professor of Microbiology at the New York University School of Medicine, Adjunct Professor of Science at New York University College of Dentistry, and Adjunct Professor of Biology, Long Island University. From 2006 to 2015, he served on the ASM International Committee and WHO Global Committee, from 2000-2012 he served as the Editor of the Clinical Microbiology Review, and 2008-2010 was Interim Director of Pathology, Bellevue Hospital Center. Dr. Hanna earned a Bachelor of Science in Biology from Saint Bonaventure University, a Masters in Science in Microbiology from Northeastern University, and a Ph.D. in Microbiology from Saint John’s University. Dr. Hanna’s post-doctorate work in Clinical Microbiology was at Mt. Sinai Hospital.

Dov Perlysky

Mr. Dov Perlysky is Independent Director of Enzo Biochem, Inc. He is currently a member of the Company’s Audit, Compensation and Nominating and Corporate Governance Committees. Mr. Perlysky became the chairman of the Compensation Committee in 2017. Mr. Perlysky has been a member of the Board of Directors of Pharma-Bio Serv, Inc. since 2004, Highlands State Bank since 2010 and News Communications since 2007. Mr. Perlysky has also been the managing member of Nesher, LLC, a private investment firm, since 2000 and a director of Engex, Inc., a closed-end mutual fund, since 1999. From 1998 until 2002, Mr. Perlysky was a vice president in the private client group of Laidlaw Global Securities, a registered broker-dealer. Mr. Perlysky received his Bachelor of Science in Mathematics and Computer Science from the University of Illinois in 1985 and his Master of Science in Management Studies from the J.L. Kellogg School of Management of Northwestern University in 1991.

Steve Anreder

Basic Compensation

Name Fiscal Year Total

Barry Weiner

1,263,830

Elazar Rabbani

1,532,000

James O'Brien

497,368

Bruce Dey

566,817

Dieter Schapfel

450,081

Gregory Bortz

185,000

Bruce Hanna

131,250

Dov Perlysky

162,500

Steve Anreder

--
As Of  31 Jul 2017

Options Compensation